Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001193125-26-211987
Q1 2026 · 10-Q
Revenue$8.21M$8.21M −12.8% vs Q1 2025−80.7% vs Q4 2025
Net Income-$9.08M-$9.08M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.54-$0.54 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$11,370,000N/M
Operating Cash Flow-$22,097,000N/M
Free Cash Flowderived-$22,116,000N/M
Margins · derived
Operating margin-138.4%−32.9 pt vs Q1 2025
Net margin-110.5%−16.9 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $8.21M | $9.42M | $5.79M | $0.00 |
| Net Income | -$9.08M | -$8.82M | -$9.08M | -$18.95M |
| EPS Diluted | -$0.54 | -$1.17 | -$1.66 | -$4.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR